Unlocking the Next
Chapter of Kidney Care
Meet the Expert Series: Video On Demand-Prof. Carol Pollock
How do we translate the Benefit in eGFR slope decline of Empagliflozin based on EMPOWER Trials from ERO, Emperor studies and EMPA-KIDNEY in clinical practice?
Related Videos
1:21
EK22||What are your thoughts on the Primary Outcome of the composite of Kidney Disease Progression results on EMPA-KIDNEY trial and implications in Practice?
2:51
EK22||What are the multiple benefits you see in the use of Empagliflozin in a patient with T2D, HF and CKD?
2:10
EK22||What is the role of Physicians in the Early diagnosis and Prompt treatment and Nephrology Referral of CKD Patients?
1:44
EK22||What are important Risk Factors considered for the development of CKD based on Epidemiology and Your practice?
Document ID: SC-ASK-00264